Robert F. Werner, an officer of Twist Bioscience Corp, filed a Form 144 notice of proposed sale on November 3, 2026, covering 148 shares of common stock with an aggregate market value of $20,039.45.

Key Highlights

  • Proposed sale: 148 shares of Twist Bioscience Corp common stock, with an aggregate market value of $20,039.45.
  • Source of shares: The 148 shares were acquired on November 2, 2026, through restricted stock vesting from the issuer, with payment classified as compensation.
  • Tax-related purpose: According to the filing, the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
  • Shares outstanding: The filing reports 62,707,424 shares of common stock outstanding at the time of notice.
  • Broker: The proposed sale is to be executed through Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.
  • Prior three-month sales: Werner sold a combined 3,410 shares between August 3, 2026, and October 2, 2026, generating gross proceeds totaling $536,614.06 across five transactions.

Werner's Proposed Share Sale Follows Restricted Stock Vesting at Twist Bioscience

Twist Bioscience Corp (NASDAQ:TWST), based at 681 Gateway Blvd., South San Francisco, California, is the subject of a Form 144 notice filed on November 3, 2026, by Robert F. Werner, identified in the filing as an officer of the company. The notice covers the proposed sale of 148 shares of common stock, with an approximate sale date of November 3, 2026, to be executed on NASDAQ through Fidelity Brokerage Services LLC.

According to the filing, the 148 shares were acquired on November 2, 2026, via restricted stock vesting directly from the issuer. The filing's remarks state that the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution," indicating the proposed sale is at least in part a tax-withholding transaction tied to equity compensation.

The filing also discloses Werner's sales activity over the prior three months. Those transactions included sales of 167 shares on August 3, 2026 (gross proceeds of $14,248.64); 669 shares on August 21, 2026 ($93,035.42); 854 shares on August 24, 2026 ($120,219.72); 238 shares on September 8, 2026 ($29,184.49); and 1,482 shares on October 2, 2026 ($279,925.79), according to the filing.

What Was Disclosed

Robert F. Werner, an officer of Twist Bioscience Corp, filed a Form 144 on November 3, 2026, disclosing a proposed sale of 148 shares of common stock valued at $20,039.45, acquired one day earlier through restricted stock vesting, partly to cover tax obligations.